Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000651112 | SCV000772962 | likely benign | Dyskeratosis congenita, autosomal recessive 5; Pulmonary fibrosis and/or bone marrow failure, Telomere-related, 3 | 2025-01-30 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001564499 | SCV001787674 | uncertain significance | not provided | 2021-03-02 | criteria provided, single submitter | clinical testing | Identified in two individuals with suspected familial bone marrow failure, one with shortened telomeres that also carried a variant in TERT, and another with normal telomere length (Marsh 2018); In silico analysis supports that this missense variant does not alter protein structure/function; Also known as M320T (c.959T>C); This variant is associated with the following publications: (PMID: 29344583) |
Sema4, |
RCV001276035 | SCV002535815 | uncertain significance | Dyskeratosis congenita | 2021-09-23 | criteria provided, single submitter | curation | |
Ce |
RCV001564499 | SCV004150975 | uncertain significance | not provided | 2022-07-01 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001276035 | SCV001461863 | likely benign | Dyskeratosis congenita | 2020-09-16 | no assertion criteria provided | clinical testing | |
Genetic Services Laboratory, |
RCV003151119 | SCV003840010 | uncertain significance | not specified | 2022-05-18 | no assertion criteria provided | clinical testing | DNA sequence analysis of the RTEL1 gene demonstrated a sequence change, c.1031T>C, in exon 12 that results in an amino acid change, p.Met344Thr (cDNA transcript used: NM_032957.4). This sequence change has been described in the gnomAD database with a frequency of 0.22% in the European Finnish subpopulation (dbSNP rs143550996). The p.Met344Thr change affects a poorly conserved amino acid residue located in a domain of the RTEL1 protein that is known to be functional. The p.Met344Thr substitution appears to be benign using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). This sequence change does not appear to have been previously described in individuals with RTEL1-related disorders. Due to insufficient evidences and the lack of functional studies, the clinical significance of the p.Met344Thr change remains unknown at this time. |